ASEAN Point of Care Diagnostics - Company Evaluation Report, 2025

The ASEAN Point of Care Diagnostics Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for ASEAN Point of Care Diagnostics. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and industry trends. The analyst's '360 Quadrants' evaluated over 62 companies, of which the Top 15 ASEAN Point of Care Diagnostics Companies were categorized and recognized as quadrant leaders.

The 360 Quadrant maps the ASEAN Point of Care Diagnostics companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the ASEAN Point of Care Diagnostics quadrant. The top criteria for product footprint evaluation included Product [Infectious Disease Testing Products (HIV Testing Products, Respiratory Infection Testing Products [TB Testing Products, Influenza Testing Products, Other Respiratory Infection Testing Products], Mosquito-borne Disease Testing Products, STD Testing Products, Hepatitis Testing Products [Hepatitis B Testing Products, Hepatitis C Testing Products], HAI Testing Products, Other Infectious Disease Testing Products), COVID-19 Testing Products, Glucose Monitoring Products (Glucose Test Strips, Glucometers, Lancets), Cardiometabolic Testing Products (Cardiac Marker Testing Products, HBA1C Testing Products, Blood Gas & Electrolyte Testing Products), Coagulation Monitoring Products, Pregnancy & Fertility Testing Products, Urinalysis Testing Products, Cancer Marker Testing Products, Cholesterol Testing Products, Hematology Testing Products, Fecal Occult Testing Products, Drugs-of-abuse Testing Products, Other POC Products], Technology [Lateral Flow Assays (Immunoassays), Rapid Tests (Molecular Diagnostics), Biochemistry], End User [Clinical Laboratories, Hospitals and Critical Care Centers, Outpatient Settings and Ambulatory Care Centers, Home Care Settings, Other End Users].

Key Players:

Major vendors in the ASEAN Point of Care Diagnostics market are Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Sysmex Corporation (Japan), Danaher Corporation (US), BD (US), QuidelOrtho Corporation (US), Cardinal Health (US), AccuBioTech Co., Ltd. (China), EKF Diagnostics Holdings plc (UK), bioMérieux (France), Thermo Fisher Scientific Inc. (US), BIOSYNEX SA (France), PTS Diagnostics (US), LifeScan IP Holdings, LLC (US), SD Biosensor, INC. (South Korea), CTK Biotech, Inc. (US), Wondfo (China), Trinity Biotech (Ireland), SEKISUI Diagnostics (US), Werfen (Spain), and ARKRAY, Inc. (US). The key strategies major vendors implement in the ASEAN Point of Care Diagnostics market are partnerships, collaborations, product launches, and product enhancements.

Abbott

Abbott is a leading diversified global healthcare company with strong market positions in diagnostics, medical devices, nutrition, and established pharmaceuticals. It is renowned for its market-leading Freestyle Libre glucose monitoring system, Alinity diagnostic platforms, and cardiovascular devices. Strategically, Abbott is focused on driving growth through continuous innovation in its medical device and diagnostics portfolios, particularly in diabetes care and structural heart. This approach, combined with its strong presence in emerging markets like India, ensures its continued influence on global health and wellness.

F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche is a global pioneer in healthcare, uniquely positioned with world-leading divisions in both Pharmaceuticals and Diagnostics. The Swiss company is a powerhouse in oncology and immunology and is the global market leader in in-vitro diagnostics with its cobas® platforms. Roche’s core strategy is Personalized Healthcare, leveraging insights from its diagnostics business to develop targeted therapies and guide clinical decisions. By combining these synergistic strengths, Roche continues to drive medical innovation and shape the future of individualized patient care worldwide.

Siemens Healthineers AG

Siemens Healthineers is a leading global medical technology company with dominant positions in diagnostic imaging, laboratory diagnostics, and cancer care. Following its transformative acquisition of Varian, the German firm now offers a uniquely comprehensive portfolio, from MRI and CT scanners to advanced radiation therapy systems. Its strategy focuses on integrating these capabilities to create end-to-end solutions, particularly in oncology, while embedding AI across its platforms to improve diagnostics and automate workflows. This positions the company as a key innovator in shaping the digitalization and future of healthcare.

1 Introduction

1.1 Market Definition
1.2 Key Stakeholders

2 Executive Summary

3 Market Overview

3.1 Introduction
3.2 Market Dynamics
3.2.1 Drivers
3.2.1.1 Rising Incidence of Infectious Diseases
3.2.1.2 Increasing Prevalence of Chronic Diseases
3.2.1.3 Favorable Government Initiatives for Poc Testing
3.2.1.4 Rising Number of Public-Private Partnerships (Ppps)
3.2.2 Restraints
3.2.2.1 Pricing Pressure on Manufacturers
3.2.2.2 Stringent Regulatory Approval Process for Product Commercialization
3.2.3 Opportunities
3.2.3.1 Gradual Shift Toward Decentralized Healthcare Systems
3.2.3.2 Availability of Poc Tests with Multiplexing Capabilities
3.2.4 Challenges
3.2.4.1 Shortage of Skilled Healthcare Providers
3.2.4.2 Premium Pricing of Novel Platforms
3.3 Trends/Disruptions Impacting Customers’ Businesses
3.4 Value Chain Analysis
3.5 Supply Chain Analysis
3.6 Ecosystem Analysis
3.7 Technology Analysis
3.7.1 Key Technologies
3.7.1.1 Lateral Flow Assays
3.7.2 Complementary Technologies
3.7.2.1 Molecular Diagnostics
3.7.3 Adjacent Technologies
3.7.3.1 Biochemical Technologies
3.8 Patent Analysis
3.9 Key Conferences & Events, 2025-2026
3.10 Porter's Five Forces Analysis
3.10.1 Threat of New Entrants
3.10.2 Threat of Substitutes
3.10.3 Bargaining Power of Buyers
3.10.4 Bargaining Power of Suppliers
3.10.5 Intensity of Competitive Rivalry
3.11 Impact of AI on Asean Point of Care Diagnostics Market
3.11.1 Introduction
3.11.2 Market Potential of AI in Poc Diagnostic Applications
3.11.3 AI Use Cases
3.11.4 Key Companies Implementing AI
3.11.5 Future of AI in Asean Point of Care Diagnostics Market

4 Competitive Landscape

4.1 Introduction
4.2 Key Player Strategies/Right to Win
4.2.1 Overview of Strategies Adopted by Players in Asean Point of Care Diagnostics Market
4.3 Revenue Analysis, 2022-2024
4.4 Market Share Analysis, 2024
4.5 Company Evaluation Matrix: Key Players, 2024
4.5.1 Stars
4.5.2 Emerging Leaders
4.5.3 Pervasive Players
4.5.4 Participants
4.5.5 Company Footprint, Key Players, 2024
4.5.5.1 Company Footprint
4.5.5.2 Country Footprint
4.5.5.3 Product Footprint
4.5.5.4 Technology Footprint
4.6 Company Evaluation Matrix: Startups/SMEs, 2024
4.6.1 Progressive Companies
4.6.2 Responsive Companies
4.6.3 Dynamic Companies
4.6.4 Starting Blocks
4.6.5 Competitive Benchmarking: Startups/SMEs, 2024
4.6.5.1 Detailed List of Key Startups/SMEs
4.6.5.2 Competitive Benchmarking of Key Startups/SMEs, by Technology
4.6.5.3 Competitive Benchmarking of Key Startups/SMEs, by Country
4.7 Company Valuation & Financial Metrics
4.7.1 Financial Metrics
4.7.2 Company Valuation
4.8 Brand/Product Comparison
4.9 Competitive Scenario
4.9.1 Product Launches & Approvals
4.9.2 Deals
4.9.3 Expansions

5 Company Profiles

5.1 Key Players
5.1.1 Abbott
5.1.1.1 Business Overview
5.1.1.2 Products Offered
5.1.1.3 Recent Developments
5.1.1.3.1 Product Approvals
5.1.1.3.2 Deals
5.1.1.4 Analyst's View
5.1.1.4.1 Key Strengths
5.1.1.4.2 Strategic Choices
5.1.1.4.3 Weaknesses & Competitive Threats
5.1.2 F. Hoffmann-La Roche Ltd.
5.1.2.1 Business Overview
5.1.2.2 Products Offered
5.1.2.3 Recent Developments
5.1.2.3.1 Product Launches & Approvals
5.1.2.3.2 Deals
5.1.2.4 Analyst's View
5.1.2.4.1 Key Strengths
5.1.2.4.2 Strategic Choices
5.1.2.4.3 Weaknesses & Competitive Threats
5.1.3 Siemens Healthineers AG
5.1.3.1 Business Overview
5.1.3.2 Products Offered
5.1.3.3 Recent Developments
5.1.3.3.1 Product Approvals
5.1.3.3.2 Deals
5.1.3.3.3 Expansions
5.1.3.4 Analyst's View
5.1.3.4.1 Key Strengths
5.1.3.4.2 Strategic Choices
5.1.3.4.3 Weaknesses & Competitive Threats
5.1.4 Sysmex Corporation
5.1.4.1 Business Overview
5.1.4.2 Products Offered
5.1.4.3 Recent Developments
5.1.4.3.1 Expansions
5.1.4.4 Analyst's View
5.1.4.4.1 Key Strengths
5.1.4.4.2 Strategic Choices
5.1.4.4.3 Weaknesses & Competitive Threats
5.1.5 Danaher Corporation
5.1.5.1 Business Overview
5.1.5.2 Products Offered
5.1.5.3 Analyst's View
5.1.5.3.1 Key Strengths
5.1.5.3.2 Strategic Choices
5.1.5.3.3 Weaknesses and Competitive Threats
5.1.6 Bd
5.1.6.1 Business Overview
5.1.6.2 Products Offered
5.1.6.3 Recent Developments
5.1.6.3.1 Deals
5.1.6.3.2 Expansions
5.1.7 Quidelortho Corporation
5.1.7.1 Business Overview
5.1.7.2 Recent Developments
5.1.7.2.1 Product Approvals
5.1.7.2.2 Deals
5.1.7.2.3 Expansions
5.1.8 Cardinal Health
5.1.8.1 Business Overview
5.1.8.2 Products Offered
5.1.8.3 Recent Developments
5.1.8.3.1 Deals
5.1.8.3.2 Expansions
5.1.9 Biomérieux
5.1.9.1 Business Overview
5.1.9.2 Products Offered
5.1.9.3 Recent Developments
5.1.9.3.1 Product Approvals
5.1.9.3.2 Deals
5.1.10 Ekf Diagnostics Holdings PLC
5.1.10.1 Business Overview
5.1.10.2 Products Offered
5.1.10.3 Recent Developments
5.1.10.3.1 Product Launches
5.1.10.3.2 Deals
5.1.10.3.3 Expansions
5.1.11 Thermo Fisher Scientific Inc.
5.1.11.1 Business Overview
5.1.11.2 Products Offered
5.1.11.3 Recent Developments
5.1.11.3.1 Product Launches
5.1.11.3.2 Deals
5.1.12 Accubiotech, Co. Ltd.
5.1.12.1 Business Overview
5.1.12.2 Products Offered
5.1.12.3 Recent Developments
5.1.12.3.1 Product Approvals
5.2 Other Players
5.2.1 Biosynex SA
5.2.2 Sd Biosensor, Inc.
5.2.3 Sekisui Diagnostics
5.2.4 Werfen
5.2.5 Trinity Biotech
5.2.6 Pts Diagnostics
5.2.7 Lifescan IP Holdings, LLC
5.2.8 Ctk Biotech, Inc.
5.2.9 Wondfo
5.2.10 Arkray, Inc.
5.2.11 Xiamen Boson Biotech Co. Ltd.
5.2.12 Credo Diagnostics Biomedical Pte. Ltd.
5.2.13 Anbio Biotechnology Inc.
5.2.14 Sg Diagnostics

6 Appendix

6.1 Research Methodology
6.1.1 Research Data
6.1.1.1 Secondary Data
6.1.1.2 Primary Data
6.1.2 Research Assumptions
6.1.3 Research Limitations
6.1.4 Risk Assessment
6.2 Company Evaluation Matrix: Methodology

List of Tables

Table 1 Hepatitis Disease Burden and Deaths Caused by Hepatitis, by Country (2022)
Table 2 Diabetes Estimates (Ages 20-79) and Diabetes-Related Deaths, by Country, 2021
Table 3 Projected Increase in Cancer Patients, by Country, 2022 vs. 2035 vs. 2045
Table 4 Asean Point of Care Diagnostics Market: Role in Ecosystem
Table 5 Asean Point of Care Diagnostics Market: Innovations & Patent Registrations, 2022-2024
Table 6 Asean Poc Diagnostics Market: Key Conferences & Events, 2025-2026
Table 7 Overview of Strategies Deployed by Key Companies in Asean Point of Care Diagnostics Market, January 2021-March 2025
Table 8 Asean Point of Care Diagnostics Market: Degree of Competition
Table 9 Asean Point of Care Diagnostics Market: Country Footprint
Table 10 Asean Point of Care Diagnostics Market: Product Footprint
Table 11 Asean Point of Care Diagnostics Market: Technology Footprint
Table 12 Asean Point of Care Diagnostics Market: Detailed List of Key Startups/SMEs
Table 13 Asean Point of Care Diagnostics Market: Competitive Benchmarking of Key Startups/SMEs, by Technology
Table 14 Asean Point of Care Diagnostics Market: Competitive Benchmarking of Key Startups/SMEs, by Country
Table 15 Asean Point of Care Diagnostics Market: Product Launches & Approvals, January 2021-March 2025
Table 16 Asean Point of Care Diagnostics Market: Deals, January 2021-March 2025
Table 17 Asean Point of Care Diagnostics Market: Expansions, January 2021-March 2025
Table 18 Abbott: Company Overview
Table 19 Abbott: Products Offered
Table 20 Abbott: Product Approvals, January 2021-March 2025
Table 21 Abbott: Deals, January 2021- March 2025
Table 22 F. Hoffmann-La Roche Ltd.: Company Overview
Table 23 F. Hoffmann-La Roche Ltd.: Products Offered
Table 24 F. Hoffmann-La Roche Ltd.: Product Launches & Approvals, January 2021-March 2025
Table 25 F. Hoffmann-La Roche Ltd.: Deals, January 2021- March 2025
Table 26 Siemens Healthineers AG: Company Overview
Table 27 Siemens Healthineers AG: Products Offered
Table 28 Siemens Healthineers AG: Product Approvals, January 2021-March 2025
Table 29 Siemens Healthineers AG: Deals, January 2021- March 2025
Table 30 Siemens Healthineers AG: Expansions, January 2021- March 2025
Table 31 Sysmex Corporation: Company Overview
Table 32 Sysmex Corporation: Products Offered
Table 33 Sysmex Corporation: Expansions, January 2021-March 2025
Table 34 Danaher Corporation: Company Overview
Table 35 Danaher Corporation: Products Offered
Table 36 Bd: Company Overview
Table 37 Bd: Products Offered
Table 38 Bd: Deals, January 2021-March 2025
Table 39 Bd: Expansions, January 2021-March 2025
Table 40 Quidelortho Corporation: Company Overview
Table 41 Quidelortho Corporation: Products Offered
Table 42 Quidelortho Corporation: Product Approvals, January 2021-March 2025
Table 43 Quidelortho Corporation: Deals, January 2021-March 2025
Table 44 Quidelortho Corporation: Expansions, January 2021-March 2025
Table 45 Cardinal Health: Company Overview
Table 46 Cardinal Health: Products Offered
Table 47 Cardinal Health: Deals, January 2021-March 2025
Table 48 Cardinal Health: Expansions, January 2021-March 2025
Table 49 Biomérieux: Company Overview
Table 50 Biomérieux: Products Offered
Table 51 Biomérieux: Product Approvals, January 2021-March 2025
Table 52 Biomérieux: Deals, January 2021-March 2025
Table 53 Ekf Diagnostics Holdings PLC: Company Overview
Table 54 Ekf Diagnostics Holdings PLC: Products Offered
Table 55 Ekf Diagnostics Holdings PLC: Product Launches, January 2021-March 2025
Table 56 Ekf Diagnostics Holdings PLC: Deals, January 2021-March 2025
Table 57 Ekf Diagnostics Holdings PLC: Expansions, January 2021-March 2025
Table 58 Thermo Fisher Scientific Inc.: Company Overview
Table 59 Thermo Fisher Scientific Inc.: Products Offered
Table 60 Thermo Fisher Scientific Inc.: Product Launches, January 2021-March 2025
Table 61 Thermo Fisher Scientific Inc.: Deals, January 2021-March 2025
Table 62 Accubiotech Co. Ltd.: Company Overview
Table 63 Accubiotech Co. Ltd.: Products Offered
Table 64 Accubiotech Co. Ltd.: Product Approvals, January 2021-March 2025
Table 65 Biosynex SA: Company Overview
Table 66 Sd Biosensor, Inc.: Company Overview
Table 67 Sekisui Diagnostics: Company Overview
Table 68 Werfen: Company Overview
Table 69 Trinity Biotech: Company Overview
Table 70 Pts Diagnostics: Company Overview
Table 71 Lifescan IP Holdings, LLC: Company Overview
Table 72 Ctk Biotech, Inc.: Company Overview
Table 73 Wondfo: Company Overview
Table 74 Arkray, Inc.: Company Overview
Table 75 Xiamen Boson Biotech Co. Ltd.: Company Overview
Table 76 Credo Diagnostics Biomedical Pte. Ltd.: Company Overview
Table 77 Anbio Biotechnology Inc.: Company Overview
Table 78 Sg Diagnostics: Company Overview
Table 79 Asean Point of Care Diagnostics Market: Key Data from Primary Sources
Table 80 Asean Point of Care Diagnostics Market: Risk Assessment Analysis

List of Figures

Figure 1 Asean Point of Care Diagnostics Market, by Product, 2025 vs. 2030 (USD Million)
Figure 2 Asean Point of Care Diagnostics Market, by Technology, 2025 vs. 2030 (USD Million)
Figure 3 Asean Point of Care Diagnostics Market, by End-user, 2025 vs. 2030 (USD Million)
Figure 4 Asean Point of Care Diagnostics Market, by Country, 2025 vs. 2030 (USD Million)
Figure 5 Asean Point of Care Diagnostics Market: Drivers, Restraints, Opportunities, and Challenges
Figure 6 Estimates of Tb Incidence for Southeast Asia Region, by Age Group and Gender (2023)
Figure 7 Asean Point of Care Diagnostics Market: Trends/Disruptions Impacting Customers’ Businesses
Figure 8 Asean Point of Care Diagnostics Market: Value Chain Analysis
Figure 9 Asean Point of Care Diagnostics Market: Supply Chain Analysis
Figure 10 Asean Point of Care Diagnostics Market: Ecosystem Analysis
Figure 11 Asean Point of Care Diagnostics Market: Patent Analysis, January 2014-December 2024
Figure 12 Asean Point of Care Diagnostics Market: Porter's Five Forces Analysis
Figure 13 Asean Point of Care Diagnostics Market: Potential of AI
Figure 14 Revenue Analysis of Key Players in Asean Point of Care Diagnostics Market, 2022-2024
Figure 15 Market Share Analysis of Key Players in Asean Point of Care Diagnostics Market, 2024
Figure 16 Asean Point of Care Diagnostics Market: Company Evaluation Matrix (Key Players), 2024
Figure 17 Asean Point of Care Diagnostics Market: Company Footprint
Figure 18 Asean Point of Care Diagnostics Market: Company Evaluation Matrix (Startups/SMEs), 2024
Figure 19 EV/EBITDA of Key Vendors, 2025
Figure 20 Year-To-Date (YTD) Price Total Return and 5-Year Stock Beta of Key Vendors, 2025
Figure 21 Asean Point of Care Diagnostics Market: Brand/Product Comparison Matrix
Figure 22 Abbott: Company Snapshot (2024)
Figure 23 F. Hoffmann-La Roche Ltd.: Company Snapshot (2024)
Figure 24 Siemens Healthineers AG: Company Snapshot (2024)
Figure 25 Sysmex Corporation: Company Snapshot (2023)
Figure 26 Danaher Corporation: Company Snapshot (2024)
Figure 27 Bd: Company Snapshot (2024)
Figure 28 Quidelortho Corporation: Company Snapshot (2024)
Figure 29 Cardinal Health: Company Snapshot (2024)
Figure 30 Biomérieux: Company Snapshot (2024)
Figure 31 Ekf Diagnostics Holdings PLC: Company Snapshot (2023)
Figure 32 Thermo Fisher Scientific Inc.: Company Snapshot (2024)
Figure 33 Asean Point of Care Diagnostics Market: Research Design
Figure 34 Asean Point of Care Diagnostics Market: Research Assumptions

Companies Mentioned

Abbott
F. Hoffmann-La Roche Ltd.
Siemens Healthineers AG
Sysmex Corporation
Danaher Corporation
Bd
Quidelortho Corporation
Cardinal Health
Biomérieux
Ekf Diagnostics Holdings PLC
Thermo Fisher Scientific Inc.
Accubiotech, Co. Ltd.
Biosynex SA
Sd Biosensor, Inc.
Sekisui Diagnostics
Werfen
Trinity Biotech
Pts Diagnostics
Lifescan IP Holdings, LLC
Ctk Biotech, Inc.
Wondfo
Arkray, Inc.
Xiamen Boson Biotech Co. Ltd.
Credo Diagnostics Biomedical Pte. Ltd.
Anbio Biotechnology Inc.
Sg Diagnostics

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€2359EUR$2,650USD£2,039GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€3784EUR$4,250USD£3,270GBP

Key Players:

Abbott

F. Hoffmann-La Roche Ltd.

Siemens Healthineers AG

Table of Contents

Companies Mentioned

Related Topics

Related Reports

ASEAN Point of Care Diagnostics Market by Product (Infectious Disease (TB, Hepatitis, STDs, HAIs), Glucose, Cardiometabolic, Pregnancy, Coagulation), Technology (Lateral Flow Assays, Biochemistry, MDx), End User (Home Care, Hospitals) - Forecast to 2030

Point of Care Diagnostics Market by Product (Glucose, Infectious Disease (TB, HAI, STD), Pregnancy), Purchase Mode (Rx, OTC), Technology (Biochemistry, MDx (RT-PCR, INAAT)), Sample (Blood, Urine), End User (Home Care, Hospitals) - Global Forecast to 2029

Point-of-Care (POC) Diagnostic Market Report and Forecast 2025-2034

Point-of-Care Diagnostics Devices and Equipment Market Report 2025

Point of Care Diagnostics Market Report 2025